Relapsed and Refractory Hodgkin's Lymphoma: New Avenues? (DOI:10.1016/j.hoc.2007.06.012);Relapsed and Refractory Hodgkin's Lymphoma: New Avenues?

Hematology/Oncology Clinics of North America

Volumn 21, Issue 5, 2007, Pages 929-941

  Canellos, George P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHIMERIC ANTIBODY; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IDARUBICIN; IFOSFAMIDE; IMMUNOGLOBULIN G ANTIBODY; MDX 060; MDX O60; MELPHALAN; MEPREDNISONE; MITOXANTRONE; NAVELBINE; NITROSOUREA; PREDNISONE; PROCARBAZINE; SGN 30; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; FOLLOW UP; HODGKIN DISEASE; HUMAN; LAPAROTOMY; MORBIDITY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REED STERNBERG CELL; REVIEW; SALVAGE THERAPY; SECOND CANCER; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

EID: 34748829811     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.06.002     Document Type: Erratum

References (70)

1. Cheson B.D., Pfistner B., Juweid M., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
2. Bonadonna G., Bonfante V., Viviani S., et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 22 (2004) 2835-2841
3. Engert A., Schiller P., Josting A., et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma study group. J Clin Oncol 21 (2003) 3601-3608
4. Brusamolino E., Baio A., Orlandi E., et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res 12 (2006) 6487-6493
5. Straus D.J., Portlock C.S., Qin J., et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (T) versus ABVD alone for stages I, II and IIIA nonbulky Hodgkin disease. Blood 104 (2004) 3483-3489
6. Dominguez A.R., Marquez A., Guma J., et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 15 (2004) 1798-1804
7. Meyer R.M., Gospodarowicz M.K., Connors J.M., et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada clinical trials group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 (2005) 4634-4642
8. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 339 (1998) 1506-1514
9. Canellos G.P., Anderson J.R., Propert K.J., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 327 (1992) 1478-1484
10. Canellos G.P., and Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 3346 (2002) 1417-1418
11. Stark G.L., Wood K.M., Jack F., et al. Hodgkin's disease in the elderly: a population-based study. Br J Haematol 119 (2002) 432-440
12. Engert A., Ballova V., Haverkamp H., et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's study group. J Clin Oncol 23 (2005) 5052-5060
13. Bonfante V., Santoro A., Viviani S., et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15 (1997) 528-534
14. Radman I., Basic N., Labar B., et al. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Ann Oncol 13 (2002) 1650-1655
15. Josting A., Rueffer U., Franklin J., et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma study group. Blood 96 (2000) 1280-1286
16. Longo D.L., Duffey P.L., Young R.C., et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10 (1992) 210-218
17. Diehl V., Franklin J., Pfreundschuh M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003) 2386-2395
18. Federico M., Bellei M., Brice P., et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21 (2003) 2320-2325
19. Lohri A., Barnett M., Fairey R.N., et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 77 (1991) 2292-2298
20. Josting A., Franklin J., May M., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma study group. J Clin Oncol 20 (2001) 221-230
21. Brice P., Bastion Y., Divine M., et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 78 (1996) 1293-1299
22. Moskowitz C.H., Kewalramani T., Nimer S.D., et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 124 (2004) 645-652
23. Josting A., Rudolph C., Mapara M., et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 16 (2005) 116-123
24. Ferme C., Mounier N., Divine M., et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial. J Clin Oncol 20 (2002) 467-475
25. Lazarus H.M., Loberiza F., Zhang M.-J., et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 27 (2001) 387-396
26. Brierley J.D., Rathmel A.J., Gospodarowicz M.K., et al. Late relapse after treatment for clinical stage I and II Hodgkin's disease. Cancer 79 (1997) 1422-1427
27. Bodis S., Henry-Amar M., Bosq J., et al. Late relapse in early-stage Hodgkin's disease patients enrolled on European organization for research and treatment of cancer protocols. J Clin Oncol 11 (1993) 225-232
28. Garcia-Carbonero R., Paz-Ares L., Arcediano A., et al. Favorable prognosis after late relapse of Hodgkin's disease. Cancer 83 (1998) 560-565
29. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of prognostic model. Blood 97 (2001) 616-623
30. Josting A., Rudolph C., Reiser M., et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 13 (2002) 1628-1635
31. Martin A., Fernandez-Jimenez M.C., Caballero M.D., et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 113 (2001) 161-171
32. Pfreundschuh M.G., Rueffer U., Lathan B., et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease study group. J Clin Oncol 12 (1994) 580-586
33. Santoro A., Bredenfeld H., Devizzi L., et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 18 (2000) 2615-2619
34. Kuruvilla J., Nagy T., Pintilie M., et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106 (2006) 353-360
35. Chau I., Harries M., Cunningham D., et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol 120 (2003) 970-977
36. Bartlett N., Niedzwiecki D., Johnson J., et al. A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease. Proc Am Soc Clin Oncol 22 (2003) 141 [abstract #2275]
37. Santoro A., Magagnali M., Spina M., et al. Ifosfamide, gemcitabine, and vinorelbine: a new regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 92 (2007) 35-41
38. Alexandrescu D.T., Karri S., Wiernik P.H., et al. Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease. Leuk Lymphoma 47 (2006) 641-656
39. Oyan B., Koc Y., Ozdemir E., et al. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 688-697
40. Majhail N.S., Weisdorf D.J., Defor T.E., et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 12 (2006) 1065-1072
41. Sureda A., Constans M., Irionda A., et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 16 (2005) 625-633
42. Ng A.K., Li S., Neuberg D., et al. Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease. Ann Oncol 15 (2004) 270-275
43. Santoro A., Viviana S., and Villarreal C.J.R. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 15 2 (1986) 528-534
44. Roach M., Brophy N., Cox R., et al. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 8 (1990) 623-629
45. Olver I.N., Wolf M.M., Cruickshank D., et al. Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease. An analysis of long-term follow-up. Cancer 62 (1988) 233-239
46. Horwich A., Spect L., and Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 33 (1997) 848-853
47. Ekstrand B.C., Lucas J.B., Horwitz S.M., et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101 (2003) 4285-4289
48. Rehwald U., Schulz H., Reiser M., et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma study group. Blood 101 (2003) 420-424
49. Fox K.A., Lippman S.M., Cassady J.R., et al. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. J Clin Oncol 5 (1987) 38-45
50. Brada M., Eeles R., Ashley S., et al. Salvage radiotherapy in recurrent Hodgkin's disease. Ann Oncol 3 (1992) 131-135
51. Uematsu M., Tarbell N.J., Silver B., et al. Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy. Cancer 72 (1993) 207-212
52. Campbell B., Wirth A., Milner A., et al. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure. Int J Radiat Oncol Biol Phys 63 (2005) 1538-1545
53. Josting A., Nogova L., Franklin J., et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma study group. J Clin Oncol 23 (2005) 1522-1529
54. Wendland M.M.M., Asch J.D., Pulsipher M.A., et al. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol 29 (2006) 189-195
55. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 359 (2002) 2065-2071
56. Yuen A., Rosenberg S.A., Hoppe R.T., et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89 (1997) 814-822
57. Leonard J., Rosenblatt J.D., Bartlett N.L., et al. Phase II study of SGN-30 (anti-CD30 monoclonal antibody patients with refractory or recurrent Hodgkin's disease. Blood 104 (2004) 721a [abstract #2635]
58. Ansell S.M., Byrd J.C., Horwitz S.M., et al. Phase I/II open-label dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma. Blood 104 (2004) 721a [abstract #2636]
59. Hartmann F., Renner C., Jung W., et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 7 (1973) 1873-1881
60. Borchmann P., Schnell R., Fuss I., et al. Phase I trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 100 (2002) 3101-3107
61. Schnell R., Staak O., Borchmann P., et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Can Res 8 (2002) 1779-1786
62. Falini B., Bolognesi A., Flenghi L., et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339 (1992) 1195-1196
63. Engert A., Diehl V., Schnell R., et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphomas. Blood 89 (1997) 403-410
64. Schnell R., Dietlein M., Staak J.O., et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 23 (2005) 4669-4678
65. Tepler I., Schwartz G., Parker K., et al. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 73 (1994) 1276-1285
66. Su Z., Peluso M.V., Raffegerst S.H., et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol 31 (2001) 947-958
67. Comoli P., Labirio M., Basso S., et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99 (2002) 2592-2598
68. Duralswamy J., Sherritt M., Thomson S., et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 101 (2003) 3150-3156
69. Anderlini P., Acholonu S.A., Okoroji G.-J., et al. Immunotherapy with donor leukocyte infusions (DLIS) in relapsed Hodgkin's disease (HD) following allogeneic stem cell transplantation (ALLO-SCT): CD3+ cell dose, GVHD and disease response. Blood 104 (2004) 460a [abstract #1654]
70. Re D., Thomas R.K., Behringer K., et al. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 105 (2005) 4553-4560